ERBB2 and breast neoplasm: Here we found that, at variance with its effects in other breast tumor phenotypes, acute DADS administration in HER2-overexpressing cells induced down-modulation, while longer treatments up-modulate the activation of both Akt1 and Akt2, known to promote growth and invasive potential through partially overlapping and/or opposite effects [50,52].